This NEI Small Business Innovation Research (SBIR) Cooperative Agreement grant is designed to support investigator-initiated, early-stage clinical trials proposed by small business concerns (SBCs). This funding focuses on studies with greater than minimal risk, typically Phase I or II, that aim to evaluate interventions for screening, diagnosing, preventing, or treating various vision disorders. Given the trial’s risk level, stringent performance oversight and safety monitoring are essential. Applicants are strongly advised to consult with NEI program staff before submitting any application, particularly those involving human subjects, to determine the most suitable funding opportunity and ensure compliance.
Opportunity ID: 351266
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-24-066 |
| Funding Opportunity Title: | NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.867 — Vision Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 01, 2023 |
| Last Updated Date: | Dec 01, 2023 |
| Original Closing Date for Applications: | Jan 07, 2027 |
| Current Closing Date for Applications: | Jan 07, 2027 |
| Archive Date: | Feb 12, 2027 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The NEI uses this U44 Notice of Funding Opportunity to support SBIR grant applications from small business concerns (SBCs) that propose to implement investigator-initiated, early-stage clinical trials with greater than minimal risk and typically are Phase I or II trials. The risk level of the U44 trial requires appropriate performance oversight and safety monitoring. For purposes of this NOFO, the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-24-066.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 351266 Full Announcement-PAR-24-066 -> PAR-24-066-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or before January 24, 2025 | PKG00283989 | Dec 01, 2023 | Jan 24, 2025 | View | |
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00289242 | Nov 27, 2024 | Jan 07, 2027 | View |
Package 1
Mandatory forms
351266 RR_SF424_5_0-5.0.pdf
351266 PHS398_CoverPageSupplement_5_0-5.0.pdf
351266 RR_OtherProjectInfo_1_4-1.4.pdf
351266 PerformanceSite_4_0-4.0.pdf
351266 RR_KeyPersonExpanded_4_0-4.0.pdf
351266 RR_Budget_3_0-3.0.pdf
351266 PHS398_ResearchPlan_5_0-5.0.pdf
351266 SBIR_STTR_Information_3_0-3.0.pdf
351266 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
351266 RR_SubawardBudget30_3_0-3.0.pdf
351266 PHS_AssignmentRequestForm_4_0-4.0.pdf
Package 2
Mandatory forms
351266 RR_SF424_5_0-5.0.pdf
351266 PHS398_CoverPageSupplement_5_0-5.0.pdf
351266 RR_OtherProjectInfo_1_4-1.4.pdf
351266 PerformanceSite_4_0-4.0.pdf
351266 RR_KeyPersonExpanded_4_0-4.0.pdf
351266 RR_Budget_3_0-3.0.pdf
351266 PHS398_ResearchPlan_5_0-5.0.pdf
351266 SBIR_STTR_Information_3_0-3.0.pdf
351266 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
351266 RR_SubawardBudget30_3_0-3.0.pdf
351266 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
